|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase ( IDH) 1 are high-frequency events in low-grade glioma and secondary glioblastoma, and IDH1 mutant gliomas are vulnerable to interventions.
|
30596429 |
2019 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With a long course of slowly progressing, this was a rare case of secondary glioblastoma with the absence of isocitrate dehydrogenase 1 (IDH1) gene mutation.
|
31555204 |
2019 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, semiquantitative protein expression analysis also showed higher expression levels of mutated IDH1 in secondary glioblastoma.
|
30943868 |
2019 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
According to the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 CNS WHO), IDH-mutant astrocytic gliomas comprised WHO grade II diffuse astrocytoma, IDH-mutant (AII<sub>IDHmut</sub>), WHO grade III anaplastic astrocytoma, IDH-mutant (AAIII<sub>IDHmut</sub>), and WHO grade IV glioblastoma, IDH-mutant (GBM<sub>IDHmut</sub>).
|
29687258 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH mutant glioblastoma had a distinctly higher survival profile than both rs11554137:C>T SNP and IDH wild type glioblastomas.
|
29423539 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been identified as one of the earliest events in gliomagenesis, occurring in over 70% of low grade gliomas and are present in the vast majority of secondary glioblastoma (GBM) that develop from these low-grade lesions.
|
29625108 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated gene in grade II-III glioma and secondary glioblastoma (GBM).
|
29719265 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because many ALT tumors express the mutant isocitrate dehydrogenase IDH1 R132H, including all lower grade astrocytomas and secondary glioblastoma, we examined a hypothesized role for IDH1 R132H in driving the ALT phenotype during gliomagenesis.
|
29545335 |
2018 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our findings offer novel mechanistic insight linking mutant IDH1 associated inhibition of histone demethylases with specific histone modification changes to produce global transcriptional repression in secondary glioblastoma.
|
27834733 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, with this assay, we could detect IDH1 mutation using cell-free tumor DNA derived from cerebrospinal fluid in a case of glioblastoma, IDH-mutant.
|
28353033 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our retrospective analysis suggested that the presence of an IDH1 (R132H) mutation, frontal tumor location, and WHO grade of the initial tumor are associated with OS after progression to sGBM.
|
28263929 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Arginine 132 (R132) mutations to histidine or cysteine frequently occur to cytosolic NADP<sup>+</sup> -isocitrate dehydrogenase (IDH1) in secondary glioblastoma multiforme (GBM) patients, in which GBM develops from a lower grade astroctyoma.
|
27406240 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hotspot mutations in isocitrate dehydrogenase 1 (IDH1) initiate low-grade glioma and secondary glioblastoma and induce a neomorphic activity that converts α-ketoglutarate (α-KG) to the oncometabolite D-2-hydroxyglutarate (D-2-HG).
|
28467784 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, mutations in isocitrate dehydrogenase 1/2 (IDH1/2) were discovered in 70% of low-grade glioma and secondary glioblastoma multiforme.
|
27649069 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recent 2016 WHO classification for CNS tumors categorizes diffuse glioma into two major types that include IDH wild-type glioblastoma, which is the predominant type and IDH-mutant glioblastoma, which is less common and displays better prognosis.
|
28730141 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These groups are: (1) Oligodendroglioma, IDH-mutant and 1p/19q-codeleted; (2) Astrocytoma, IDH-mutant; (3) Glioblastoma, IDH-mutant; (4) Glioblastoma, IDH-wildtype; and (5) Astrocytoma, IDH-wildtype.
|
28255664 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM).
|
28564604 |
2017 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
Biomarker
|
disease |
BEFREE |
One such difference concerns mutations in the NADP(+)-dependent isocitrate dehydrogenase (IDH1 and IDH2) genes, which occur in >80% of cases of low grade glioma and secondary glioblastoma.
|
24747768 |
2014 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutation of isocitrate dehydrogenase 1 (IDH1) is now recognized as the most common initiating event for secondary glioblastoma, a brain tumor type arising with high frequency in the frontal lobe.
|
25225364 |
2014 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the most prevalent in low-grade glioma and secondary glioblastoma, represent an early pathogenic event, and are associated with epigenetically driven modulations of metabolism.
|
24876103 |
2014 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The isocitrate dehydrogenase 1 (IDH1) mutation occurs in high frequency in glioma and secondary glioblastoma (GBM).
|
23541771 |
2013 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results showed the absence of IDH1 mutation in primary glioblastoma, confirming that this mutation is a hallmark of secondary glioblastoma.
|
22865003 |
2013 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gain-of-function mutations of the isocitrate dehydrogenase 1 (IDH1) gene are among the most prevalent in low-grade gliomas and secondary glioblastoma.
|
24019001 |
2013 |
|
Glioblastoma, IDH-Mutant
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Decisive genetic signposts of secondary glioblastoma are IDH1 mutations, which are absent in primary glioblastomas and which are associated with a hypermethylation phenotype.
|
23209033 |
2013 |